Ironwood Pharmaceuti (IRWD) Stock Price, Quote & News

Company Profile

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA name...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 617 621 7722

Fax: 617 494 0480

Website: ironwoodpharma.com

Address:

100 Summer Street, Suite 2300, Boston, United States

Solaf Jul. 29 at 2:22 PM

$IRWD we need to meet expected linzess sales numbers on Friday. A miss will mean bloodbath.

0 · Reply

MrHurts Jul. 29 at 11:06 AM

$IRWD

0 · Reply

Bio_Invest101 Jul. 28 at 10:14 PM

$IRWD So far the top 3 holders Armistices 15 Million shares at $ 5.86 per BR 13.4 Million at $12.03 per Alex Denner 9 Millions @$12.84 So for you retails nonstop complaining about $3-4 SP every day is beyond boring but stupidity. You all got the Debbie The Downer syndrome or the ghost virus. Not serious about making money.

1 · Reply

Bio_Invest101 Jul. 28 at 9:03 PM

$IRWD https://d18rn0p25nwr6d.cloudfront.net/CIK-0001446847/16c7396a-9ba7-44e8-ae61-898833a233ee.pdf

0 · Reply

StockTwitsGhost Jul. 28 at 4:48 PM

$IRWD These morons who randomly show up here touting the value of Linzess and Ironwood have absolutely no clue what the Tom McCourt and Alex Denner infused board era have truly done to shareholders. RSU vultures, channel trading the never ending short swing profit. Anyone defending them after six+ years of this either shares a bed with one of the clown brigade or doesn’t have any skin in the game. 🤡

1 · Reply

StockTwitsGhost Jul. 27 at 5:05 PM

$IRWD Hello @ OliveDrabGreen, good to see my old friend here. How is Alex?

1 · Reply

raylin Jul. 27 at 4:51 PM

$IRWD Interesting upward movement.

0 · Reply

MalekJ Jul. 27 at 1:33 PM

$IRWD

0 · Reply

Solaf Jul. 27 at 9:46 AM

$IRWD abbvie ER Friday this week. We will be waiting for linzess sales numbers. Good luck all and lets have a good week.

1 · Reply

Bio_Invest101 Jul. 27 at 9:27 AM

$IRWD This kind of early phrase pipeline buyout deal without a FDA approval yet at $2-3 B is quite suitable but highly risky, especially considering the $475 M Linzess revenues we already have, not just the APRA pipeline It’s seller market now and Tom McCourt should hold strong in his negotiations. $12 for $2 B is minimum. Stay patient for our turn. https://www.fortebiorx.com/investor-relations/news/news-details/2026/argenx-to-Acquire-Forte-Biosciences-Inc--Adding-First-in-Class-Anti-CD122-Antibody-FB102-to-Its-Immunology-Pipeline/default.aspx

1 · Reply

Ironwood CMO Michael Shetzline to retire, Jeffrey Silber to succeed

Jul 14, 2026, 7:30 AM EDT - 15 days ago

Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients

Jun 4, 2026, 11:05 AM EDT - 7 weeks ago

Ironwood Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

May 28, 2026, 4:05 PM EDT - 2 months ago

Ironwood Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

2026-05-27T15:08:53.000Z - 2 months ago

Ironwood says FDA approves use of Linzess in pediatric patients two and older

May 27, 2026, 10:00 AM EDT - 2 months ago

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

May 7, 2026, 8:30 AM EDT - 2 months ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Ironwood Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Ironwood Pharmaceuticals Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 2 months ago

Ironwood Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 7:05 AM EDT - 2 months ago

Ironwood Pharmaceuticals Reports Strong First Quarter 2026 Results With 97% Year-Over-Year LINZESS U.S. Net Sales Growth; Maintains Full-Year 2026 Financial Guidance

2026-05-04T11:11:53.000Z - 3 months ago

Ironwood presents new findings at DDW 2026 from survey treatment of SBS

May 4, 2026, 7:05 AM EDT - 3 months ago

Ironwood Survey Findings at DDW 2026 Underscore Need for Therapies that Address Multiple Dimensions of Total Parenteral Nutrition (TPN) Burden in Short Bowel Syndrome (SBS)

Apr 30, 2026, 4:05 PM EDT - 3 months ago

Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Ironwood Pharmaceuticals Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 3 months ago

Ironwood Pharmaceuticals Proxy statement: Proxy filing

2026-04-23T11:25:41.000Z - 3 months ago

Ironwood to present data from Landmark survey on SBS

Apr 23, 2026, 7:05 AM EDT - 3 months ago

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

SBS

Mar 11, 2026, 4:00 PM EDT - 4 months ago

Ironwood Pharmaceuticals Transcript: The Citizens Life Sciences Conference 2026

Mar 4, 2026, 4:05 PM EST - 5 months ago

Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference

2026-02-26T11:08:56.000Z - 5 months ago

Ironwood price target raised to $10 from $8 at Citizens

Feb 25, 2026, 8:30 AM EST - 5 months ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 25, 2026, 8:30 AM EST - 5 months ago

Ironwood Pharmaceuticals Annual report: Q4 2025

Feb 25, 2026, 8:30 AM EST - 5 months ago

Ironwood Pharmaceuticals Earnings release: Q4 2025

Feb 25, 2026, 8:30 AM EST - 5 months ago

Ironwood Pharmaceuticals Slides: Q4 2025

Feb 25, 2026, 7:05 AM EST - 5 months ago

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Results; Achieves 2025 Financial Guidance and Reiterates Strong 2026 Outlook

Feb 18, 2026, 4:21 PM EST - 5 months ago

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Investor Update Call

2026-01-05T12:37:19.000Z - 7 months ago

Craig-Hallum upgrades Ironwood to Buy following 2026 guidance

2026-01-05T12:20:08.000Z - 7 months ago

Ironwood upgraded to Buy from Hold at Craig-Hallum

2026-01-05T10:15:33.000Z - 7 months ago

Ironwood upgraded to Outperform from Market Perform at Citizens

2026-01-04T23:25:05.000Z - 7 months ago

Ironwood price target raised to $5 from $3 at Wells Fargo

2026-01-02T17:29:08.000Z - 7 months ago

Why Did Ironwood Pharma Stock (IRWD) Jump 30% Today?

PFE

Jan 2, 2026, 7:05 AM EST - 7 months ago

Ironwood Pharmaceuticals Maintains FY 2025 Financial Guidance and Announces FY 2026 Financial Guidance

Nov 10, 2025, 7:05 AM EST - 9 months ago

Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial Guidance

Nov 10, 2025, 7:00 AM EST - 9 months ago

Ironwood Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 7:00 AM EST - 9 months ago

Ironwood Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 7:00 AM EST - 9 months ago

Ironwood Pharmaceuticals Slides: Q3 2025

Oct 24, 2025, 8:10 AM EDT - 9 months ago

Ironwood Stair & Rail Inc. Recognised With 2025 Consumer Choice Award for Stairs and Railings in Southern Alberta

Aug 7, 2025, 7:05 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reports Second Quarter 2025 Results; Maintains Full Year 2025 Financial Guidance

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Earnings release: Q2 2025

May 7, 2025, 12:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals Transcript: The Citizens JMP Life Sciences Conference 2025

May 7, 2025, 7:05 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reports First Quarter 2025 Results

May 7, 2025, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Quarterly report: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Earnings release: Q1 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Proxy statement: Proxy Filing

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Proxy statement: Proxy Filing

Apr 25, 2025, 7:05 AM EDT - 1 year ago

Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Present Real-World Data at Digestive Disease Week® 2025 on Adoption of New Diagnosis Codes Among Short Bowel Syndrome Patients Who Are Dependent on Parenteral Support

Apr 14, 2025, 7:00 AM EDT - 1 year ago

Ironwood Pharmaceuticals Provides Clinical and Regulatory Update on Apraglutide

Mar 27, 2025, 4:05 PM EDT - 1 year ago

Ironwood Pharmaceuticals Announces Receipt of Nasdaq Non-Compliance Notification Regarding Late 2024 Form 10-K Filing

Mar 25, 2025, 8:30 AM EDT - 1 year ago

Industry Veteran Launches Ironwood III With Substantial Equity Commitment From Kayne Anderson Energy Infrastructure Fund

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Annual report: Q4 2024

Feb 27, 2025, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings release: Q4 2024

Feb 27, 2025, 7:00 AM EST - 1 year ago

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Results; Achieves 2024 Financial Guidance

Feb 20, 2025, 4:00 PM EST - 1 year ago

Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2024 Investor Update Call

Jan 29, 2025, 4:30 PM EST - 1 year ago

Ironwood Pharmaceuticals Transcript: Status Update

Jan 29, 2025, 4:30 PM EST - 1 year ago

Ironwood Pharmaceuticals Press release: Status Update

Jan 29, 2025, 4:05 PM EST - 1 year ago

Ironwood Pharmaceuticals Initiates Apraglutide NDA Submission, Highlights Compelling New Data and Updates Corporate Structure to Position for the Future

Jan 17, 2025, 8:07 AM EST - 1 year ago

Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications

Dec 4, 2024, 12:30 PM EST - 1 year ago

Ironwood Pharmaceuticals Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:01 PM EST - 1 year ago

Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 20, 2024, 2:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2024

Nov 13, 2024, 4:01 PM EST - 1 year ago

Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare Conference

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Quarterly report: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Earnings release: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Ironwood Pharmaceuticals Slides: Q3 2024

Nov 7, 2024, 7:00 AM EST - 1 year ago

Ironwood Pharmaceuticals Reports Third Quarter 2024 Results

Oct 28, 2024, 7:00 AM EDT - 1 year ago

Once-Weekly Apraglutide Showed Consistent Treatment Effect Across Baseline Demographics and Disease Characteristics in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF), According to New STARS Phase III Data from Ironwood at ACG 2024

Oct 24, 2024, 4:00 PM EDT - 1 year ago

Ironwood Pharmaceuticals to Host Third Quarter 2024 Investor Update Call

Sep 5, 2024, 2:15 PM EDT - 2 years ago

Ironwood Pharmaceuticals Transcript: 2024 Wells Fargo Healthcare Conference

Aug 29, 2024, 4:01 PM EDT - 2 years ago

Ironwood Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Ironwood Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Ironwood Pharmaceuticals Quarterly report: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Ironwood Pharmaceuticals Earnings release: Q2 2024

Aug 8, 2024, 8:30 AM EDT - 2 years ago

Ironwood Pharmaceuticals Slides: Q2 2024

Aug 8, 2024, 7:00 AM EDT - 2 years ago

Ironwood Pharmaceuticals Reports Second Quarter 2024 Results

Jul 25, 2024, 4:00 PM EDT - 2 years ago

Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call

Solaf Jul. 29 at 2:22 PM

$IRWD we need to meet expected linzess sales numbers on Friday. A miss will mean bloodbath.

0 · Reply

MrHurts Jul. 29 at 11:06 AM

$IRWD

0 · Reply

Bio_Invest101 Jul. 28 at 10:14 PM

1 · Reply

Bio_Invest101 Jul. 28 at 9:03 PM

$IRWD https://d18rn0p25nwr6d.cloudfront.net/CIK-0001446847/16c7396a-9ba7-44e8-ae61-898833a233ee.pdf

0 · Reply

StockTwitsGhost Jul. 28 at 4:48 PM

1 · Reply

StockTwitsGhost Jul. 27 at 5:05 PM

$IRWD Hello @ OliveDrabGreen, good to see my old friend here. How is Alex?

1 · Reply

raylin Jul. 27 at 4:51 PM

$IRWD Interesting upward movement.

0 · Reply

MalekJ Jul. 27 at 1:33 PM

$IRWD

0 · Reply

Solaf Jul. 27 at 9:46 AM

$IRWD abbvie ER Friday this week. We will be waiting for linzess sales numbers. Good luck all and lets have a good week.

1 · Reply

Bio_Invest101 Jul. 27 at 9:27 AM

1 · Reply

Libertarian_Pirate Jul. 26 at 11:31 PM

$IRWD We have one support and one trendline close to each other, combine that with the classic tapering off of selling pressure and a pattern of the chart bouncing off an RSI around 40, we should see another pop as long as the market doesn't crash due to this war.

0 · Reply

Aleexandder Jul. 24 at 9:20 PM

$IRWD Strong cash-generating flagship drug !

0 · Reply

StockTwitsGhost Jul. 24 at 8:07 PM

$IRWD #SAVEIRONWOOD

0 · Reply

StockTwitsGhost Jul. 24 at 8:05 PM

$IRWD #TomMcCourtMustGo #RETIRE

0 · Reply

MalekJ Jul. 24 at 7:58 PM

$IRWD Partnership news on Monday? maybe?

0 · Reply

StockTwitsGhost Jul. 24 at 6:48 PM

$IRWD Next stop: Macedonia, where shareholders become the deck crew

1 · Reply

MalekJ Jul. 24 at 3:52 PM

$IRWD I do not think any acquirers will come anytime soon. I do believe a partnership is more likely with IRWD. Inject cash flow to support STARS-2 and then once it is confirmed maybe a buyout.

1 · Reply

revuelto Jul. 24 at 3:44 PM

$IRWD I think that’s exactly how Tommy is vibing with potential acquirers lol…but in all seriousness, I think most of us have been incredibly patient with this name and it’s about time that patience finally pays off 🤞

0 · Reply

MalekJ Jul. 24 at 2:49 PM

$IRWD

0 · Reply

revuelto Jul. 22 at 7:34 PM

$IRWD is this what a gap up setup looks like? 🐋

1 · Reply

Bio_Invest101 Jul. 21 at 8:36 PM

$IRWD

1 · Reply

joemist1 Jul. 21 at 3:53 PM

$IRWD Hello WA pedophiles. Please move to positive direction.

0 · Reply

Market Cap	637.56M
Revenue (ttm)	296.15M
Net Income (ttm)	24.02M
EPS (ttm)	N/A
PE Ratio	6.08
Forward PE	3.57
Profit Margin	8.11%
Debt to Equity Ratio	-2.69

Volume	1,821,200
Avg Vol	2,334,214
Day's Range	N/A - N/A
Shares Out	163.06M
Stochastic %K	34%
Beta	0.20
Analysts	Strong Sell
Price Target	$5.88